Portal de Periódicos da CAPES

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

2018; Massachusetts Medical Society; Volume: 379; Issue: 2 Linguagem: Inglês

10.1056/nejmoa1803164

1533-4406

Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Eva Ciruelos, Harold J. Burstein, Hervé Bonnefoi, Meritxell Bellet, Silvana Martino, Charles E. Geyer, Matthew P. Goetz, Vered Stearns, Graziella Pinotti, Fabio Puglisi, Simon Spazzapan, Miguel Ángel Climent, L. Pavesi, Thomas Ruhstaller, Nancy E. Davidson, Robert L. Coleman, Marc Debled, Stefan Buchholz, James N. Ingle, Eric P. Winer, Rudolf Maibach, Manuela Rabaglio, Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan,

Advanced Breast Cancer Therapies

In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials.